ESPR - AlphaYou

Smart money at a glance

Filings to Oct 31, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 0 cutMore adding

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about ESPR filings

Are insiders buying or selling Esperion Therapeutics Inc (ESPR) stock?

Neither. Esperion Therapeutics Inc (ESPR) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ESPR recently?

None. No member of Congress disclosed a ESPR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ESPR smart-money data?

This summary uses filings available on Oct 31, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on ESPR

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $240K
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
- FMR LLC, added +$13.6M, holdings at Jun 30
- Two Sigma, added +$8.4M, holdings at Mar 31
Lean long · thin2 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ESPR filings

Are insiders buying or selling Esperion Therapeutics Inc (ESPR) stock?

Neither. Esperion Therapeutics Inc (ESPR) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ESPR recently?

None. No member of Congress disclosed a ESPR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ESPR smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$21.9M

Buys/Adds (2)

TS
Two Sigma
Q1 2026 13F
$8.4M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
FM
FMR LLC
Q2 2026 13F
$13.6M
added

Unlock everything for $29/month

Unlock for $29/month

Reported May 8, 2026

Earnings came in $0.10 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

May 8, 2026

Period ending

Mar 31, 2026

Earnings per share

-$0.10-$0.10 miss

-$0.00 expected

Revenue

Unavailable

Revenue data unavailable

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Mar 31, 2026Reported May 8, 2026	-$0.10est. -$0.00	-$0.10miss	Not on file	Not on file
Dec 31, 2025Reported Mar 10, 2026	$0.22est. $0.29	-24.55%miss	Not on file	Not on file
Sep 30, 2025Reported Nov 6, 2025	-$0.16est. $0.02	-$0.18miss	Not on file	Not on file
Jun 30, 2025Reported Aug 5, 2025	-$0.06est. -$0.14	+57.14%beat	Not on file	Not on file
Mar 31, 2025Reported May 6, 2025	-$0.21est. -$0.15	-37.53%miss	Not on file	Not on file
Dec 31, 2024Reported Mar 4, 2025	-$0.10est. -$0.16	+35.68%beat	Not on file	Not on file
Sep 30, 2024Reported Nov 7, 2024	-$0.15est. -$0.18	+16.67%beat	Not on file	Not on file
Jun 30, 2024Reported Aug 12, 2024	-$0.33est. -$0.18	-83.33%miss	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

52-wk high: $4.18
52-wk low: $1.10
Mkt cap: $819.5M
ROE: -260.8%
Fwd P/E: 4.6x
Beta: 1.06
P/S: 2.0x
P/B: 98.4x
Profit margin: -1.8%
Op margin: -8.2%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -1.8%
P/E: 0.00
Forward P/E: 4.64
Market cap: $819M

Valuation

P/S1.96
P/B98.42
Dividend yield0.0%

Quality

Operating margin-8.2%
ROE-260.8%
ROA12.0%

Growth

Beta1.06

Technicals

Price structure

Market data unavailable.

Smart money at a glance

Filings to Oct 31, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 0 cutMore adding

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about ESPR filings

Are insiders buying or selling Esperion Therapeutics Inc (ESPR) stock?

Neither. Esperion Therapeutics Inc (ESPR) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ESPR recently?

None. No member of Congress disclosed a ESPR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ESPR smart-money data?

13F: filed up to 45 days late.

Smart money on ESPR

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $240K
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
- FMR LLC, added +$13.6M, holdings at Jun 30
- Two Sigma, added +$8.4M, holdings at Mar 31
Lean long · thin2 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ESPR filings

Are insiders buying or selling Esperion Therapeutics Inc (ESPR) stock?

Neither. Esperion Therapeutics Inc (ESPR) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ESPR recently?

None. No member of Congress disclosed a ESPR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ESPR smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$21.9M

Buys/Adds (2)

TS
Two Sigma
Q1 2026 13F
$8.4M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
FM
FMR LLC
Q2 2026 13F
$13.6M
added

Unlock everything for $29/month

Unlock for $29/month

Reported May 8, 2026

Earnings came in $0.10 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

May 8, 2026

Period ending

Mar 31, 2026

Earnings per share

-$0.10-$0.10 miss

-$0.00 expected

Revenue

Unavailable

Revenue data unavailable

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Mar 31, 2026Reported May 8, 2026	-$0.10est. -$0.00	-$0.10miss	Not on file	Not on file
Dec 31, 2025Reported Mar 10, 2026	$0.22est. $0.29	-24.55%miss	Not on file	Not on file
Sep 30, 2025Reported Nov 6, 2025	-$0.16est. $0.02	-$0.18miss	Not on file	Not on file
Jun 30, 2025Reported Aug 5, 2025	-$0.06est. -$0.14	+57.14%beat	Not on file	Not on file
Mar 31, 2025Reported May 6, 2025	-$0.21est. -$0.15	-37.53%miss	Not on file	Not on file
Dec 31, 2024Reported Mar 4, 2025	-$0.10est. -$0.16	+35.68%beat	Not on file	Not on file
Sep 30, 2024Reported Nov 7, 2024	-$0.15est. -$0.18	+16.67%beat	Not on file	Not on file
Jun 30, 2024Reported Aug 12, 2024	-$0.33est. -$0.18	-83.33%miss	Not on file	Not on file

52-wk high: $4.18
52-wk low: $1.10
Mkt cap: $819.5M
ROE: -260.8%
Fwd P/E: 4.6x
Beta: 1.06
P/S: 2.0x
P/B: 98.4x
Profit margin: -1.8%
Op margin: -8.2%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -1.8%
P/E: 0.00
Forward P/E: 4.64
Market cap: $819M

Valuation

P/S1.96
P/B98.42
Dividend yield0.0%

Quality

Operating margin-8.2%
ROE-260.8%
ROA12.0%

Growth

Beta1.06

Technicals

Price structure

Market data unavailable.

Esperion Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about ESPR filings

Smart money on ESPR

Questions about ESPR filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.10 a share below what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Esperion Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about ESPR filings

Smart money on ESPR

Questions about ESPR filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.10 a share below what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Esperion Therapeutics Inc

Overview

Questions about ESPR filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Esperion Therapeutics Inc

Overview

Questions about ESPR filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.